Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.61 |
| ▸ | CTSS | P25774 | 9/20 | 0.61 |
| ▸ | CTSK | P43235 | 6/20 | 0.61 |
| ▸ | CTSB | P07858 | 5/20 | 0.61 |
| ▸ | PYGL | P06737 | 7/20 | 0.58 |
| ▸ | CTSV | O60911 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529198 | 0.87 | PYGL (0.54) | CTSLCTSSCTSKCTSBPYGL | |
| SCHEMBL6590407 | 0.84 | CTSL (0.74) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5526795 | 0.84 | CTSL (0.74) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5528430 | 0.83 | CTSL (0.70) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5529205 | 0.83 | PYGL (0.55) | CTSLCTSSCTSKCTSBPYGL | |
| SCHEMBL5522778 | 0.81 | CTSL (0.78) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5528519 | 0.80 | CTSL (0.80) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5526298 | 0.80 | CTSL (0.80) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5528523 | 0.80 | CTSL (0.80) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5526263 | 0.80 | CTSL (0.80) | CTSLCTSSCTSKCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSL 14/4885CTSS 10/4885CTSK 32/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | CTSL 14/4885CTSS 10/4885CTSK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.